ArticleESMO real world data and digital oncology2026

Registry-based randomised phase II study of Enzalutamide versus Abiraterone: assessing cognitive function in eLderly patients with metastatic castration-resistant Prostate cancer (REAL-Pro).

A Anton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.